Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.

Trial Details

NCT ID
NCT06864624
Phase
PHASE2
Sponsor
Tang-Du Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Sunvozertinib
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Yinchuan, Ningxia, China|38.46806,106.27306
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Patients must understand the requirements and content of the clinical trial and provide a handwritten signed and dated informed consent.
  • Age ≥ 18 years old.
  • Non-small cell lung cancer confirmed by histopathology or cytology, clinical stage II, IIIA or IIIB (N2) assessed by the investigator according to …
  • EGFR exon 20 insertion mutation confirmed by an approved local laboratory.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →